Diagnostics firm invests £11m in rapid testing system



QuantuMDx Group is leading the development of the new test

A Newcastle-headquartered diagnostics firm has invested more than £11m in the development of its flagship rapid point-of-care testing system.

QuantuMDx Group’s Q-POC is a portable, PCR device offering rapid, sample-to-answer, molecular diagnostic testing at the point of care, with results in approximately 30 minutes. The system comprises a sample collection kit, single-use test cassette and analyser.

The company’s first commercial assay for Q-POC will detect SARS-CoV-2, the virus causing COVID-19, and Flu A and B, providing a rapid PCR diagnostics and surveillance tool for clinicians and public health officials.

Jonathan O’Halloran, CEO of QuantuMDx, said: “We have developed the Q-POC over the past 10 years and created one of the fastest, most accurate and powerful PCR diagnostic devices on the market, and at the right time to be able to respond to the pandemic.

“We have spent the last 10 months scaling our manufacturing for both our Q-POC and first commercial test cassette and are presently running performance evaluation studies to confirm performance in real-life clinical settings.

QuantuMDx has worked with British development partner Cambridge Design Partnership to undertake pilot manufacturing of Q-POC and is now working with Cogent Technology as the company scales for volume manufacturing.

Cogent Technology operates an 80,000 sq ft facility in Felixstowe and has procured a new surface mount assembly line specifically for QuantuMDx, which includes an automated optical inspection machine.

O’Halloran added: “We’re delighted to be working with Univac, RD Support and fellow British partners Cogent and CDP to support the international response to COVID-19 testing.

“Scaling-up was always going to be a challenge, especially during a global pandemic, but with the commitment, focus and dedication of everyone involved with QuantuMDx and our partners, we’ll soon be able to introduce our rapid, point of care diagnostic solution to benefit frontline health workers across the globe.

“With the large manufacturing scale that we have achieved, QuantuMDx is poised to become an important player in the molecular diagnostics industry.”

QuantuMDx expects to achieve CE-IVD marking for its Q-POC system in early 2021 following a release for research use only.


Trending stories

Exit mobile version